Who are Reglan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Motilium, Drug either PPIS or H2RA and prokinetics, Metoclopramide hydrochloride monohydrate, DA-9701, Motilitone® and Pantoline®, Placebo domperidone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metoclopramide-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Reglan — Competitive Intelligence Brief

Reglan (Metoclopramide Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prokinetic agent. Area: Metabolic.

marketed Prokinetic agent Acetylcholine receptor sensitization; dopamine antagonism (implied) Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Reglan (Metoclopramide Hydrochloride) — Hikma. Metoclopramide stimulates upper GI tract motility by sensitizing tissues to acetylcholine action.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reglan TARGET	Metoclopramide Hydrochloride	Hikma	marketed	Prokinetic agent	Acetylcholine receptor sensitization; dopamine antagonism (implied)	1979-01-01
Motilium	domperidone	Johnson & Johnson (Janssen)	marketed	Prokinetic agent / Antiemetic	Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2	1978-01-01
Drug either PPIS or H2RA and prokinetics	Drug either PPIS or H2RA and prokinetics	King Saud University	marketed	Combination antacid and prokinetic agent	H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target
Metoclopramide hydrochloride monohydrate	Metoclopramide hydrochloride monohydrate	CM Chungmu Hospital	marketed	Dopamine antagonist / Antiemetic / Prokinetic agent	Dopamine D2 receptor
DA-9701	DA-9701	Seoul National University Hospital	marketed	Prokinetic agent	Dopamine receptor antagonist; acetylcholinesterase inhibitor
Motilitone® and Pantoline®	Motilitone® and Pantoline®	Dong-A ST Co., Ltd.	marketed	Prokinetic agent	Dopamine receptor antagonist; acetylcholinesterase inhibitor
Placebo domperidone	Placebo domperidone	Seoul National University Hospital	marketed	Dopamine antagonist / Prokinetic agent	Dopamine D2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-12-22 — Reglan · 11813231 · Formulation · US
2029-12-22 — Reglan · 12194009 · Method of Use · US
2029-12-22 — Reglan · 12194008 · Method of Use · US
2029-12-22 — Reglan · 11020361 · Method of Use · US
2029-12-22 — Reglan · 11628150 · Formulation · US
2030-05-16 — Reglan · 8334281 · Formulation · US
2038-11-17 — Reglan · 12377064 · Method of Use · US

Sponsor landscape (Prokinetic agent class)

Dong-A ST Co., Ltd. · 1 drug in this class
Hikma · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reglan — Competitive Intelligence Brief. https://druglandscape.com/ci/metoclopramide-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab